A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Type of Cancer
Leukemia

Sponsor
Astex Pharmaceuticals

Protocol Number
ASTX727-02

To Learn More Call
(201)-510-0950